Evidence map›Paper›PMID 40644465›Full record

ArticlePloS one2025

Calcium-dependent pathway as a primary cause of hypoxic RGC damage in monkey retinal explants.

Emi Nakajima, Momoko Otsugu-Kobayashi, Takatoshi Uchida, Kana Orihara, Thomas R Shearer, Mitsuyoshi Azuma

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emi NakajimaSenju Laboratory of Ocular Sciences, Senju Pharmaceutical Corporation Limited, Portland, Oregon, United States of America.
Momoko Otsugu-KobayashiSenju Laboratory of Ocular Sciences, Senju Pharmaceutical Corporation Limited, Kobe, Japan.
Takatoshi UchidaSenju Laboratory of Ocular Sciences, Senju Pharmaceutical Corporation Limited, Portland, Oregon, United States of America.
Kana OriharaSenju Laboratory of Ocular Sciences, Senju Pharmaceutical Corporation Limited, Portland, Oregon, United States of America.
Thomas R ShearerDepartment of Integrative Biomedical & Diagnostic Sciences, Oregon Health & Science University, Portland, Oregon, United States of America.
Mitsuyoshi AzumaSenju Laboratory of Ocular Sciences, Senju Pharmaceutical Corporation Limited, Portland, Oregon, United States of America.ORCID https://orcid.org/0000-0002-3593-1476

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRetinal ganglion cells (RGCs) loss or degeneration in the retina is a hallmark of many sight-threatening diseases, including glaucoma and retinopathy. In our previous studies, calcium-activated cysteine protease calpain induced RGC damage under hypoxia/reoxygenation in the monkey retina explants, and the calpain inhibitor SNJ-1945 partially inhibited RGC damage. Calcium-independent proteases such as cathepsins exist in the retina, although the involvement of cathepsins in hypoxia-induced RGC damage is unclear. The purpose of the present study is to determine if cathepsins are involved in RGC damage during hypoxia/reoxygenation and to elucidate the role of calcium.

methodsThe cathepsin inhibitors (Odanacatib and SID26681509) were tested for their specificity against three cathepsins in vitro. Calpain inhibitors (SNJ-1945, PD-151746, ABT-957, and C2I) were tested for their isozyme specificity in vitro. Monkey retinal explants were cultured under hypoxic conditions with 0.3% oxygen in the chamber, followed by reoxygenation. The calpain- or cathepsin-specific inhibitors were added to the hypoxic culture medium. BAPTA and BAPT-AM were also used to determine the calcium requirement in RGC damage. After the cultured period, retinal explants were prepared for flat mounts and retinal lysates. The flat mounted retinas were stained with propidium Iodide (PI) to assess RGC damage and with an antibody specific for calpain-specific α-spectrin break down product 150 kDa (SBDP150). Immunoblotting assays were performed for α-spectrin and calpains.

resultsThe cathepsin inhibitors were confirmed to be specific to cathepsin without calpain inhibitory effects in vitro. The number of PI-positive RGCs increased in the hypoxic monkey retina; however, cathepsin inhibitors did not mitigate RGC damage. In contrast, RGC damage was completely inhibited by BAPTA and partially by BAPTA-AM. In hypoxic retinas, calpain-specific SBDP150 increased in the nerve fiber layer (NFL). Immunoblotting revealed an increase in SBDP150 and the activation of calpain 1. These changes were inhibited by BAPTA or BAPTA-AM, with BAPTA demonstrating a stronger effect compared to BAPTA-AM. Calpain inhibitors demonstrated lower specificity in vitro than previously reported. In hypoxic retina, each calpain inhibitor alleviated RGC damage and reduced SBDP150-positive staining in NFL. Furthermore, calpain inhibitors attenuated the activation of calpain 1 and the breakdown of α-spectrin, as assessed by immunoblotting.

conclusionsCalcium-independent cathepsins do not contribute to RGC damage in monkey retinal explants cultured under hypoxia/reperfusion. In contrast, calcium influx from extracellular sources plays a critical role in inducing RGC damage. Elevated intracellular calcium levels could activate calpains, leading to RGC damage; however, other calcium-dependent pathways might also be involved in this process.

Indexed as

CalciumRetinaRetinal Ganglion CellsAnimalsCalpainCarbamatesCathepsinsCell Hypoxia((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl esterCalciumCalpainCarbamatesCathepsins

Identifiers

PMID40644465
PMCPMC12250347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.